Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes: a double blind RCT

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502082-22-00

Acronym

S66967

Enrollment

252

Registered

2023-05-22

Start date

2023-09-14

Completion date

Unknown

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prediabetes

Brief summary

The development of type 2 diabetes (T2DM) by 160 weeks defined by fasting glycaemia, OGTT and/or HbA1c according to the ADA criteria1

Detailed description

Secondary outcomes by 160 weeks (end of treatment) and by 172-184 weeks (3-6 months after stop medication): such as need for rescue therapy for diabetes, prediabe, regression to normoglycaemia, mean BMI, waist circumference, waist/hip circumference, weight loss ≥5%, ≥10% and ≥15%, body fat percentage measured by bioelectrical impedance analysis and Beta-cell function

Interventions

DRUGplacebo for injection in pre-filled pen

DRUGOzempic 1 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The development of type 2 diabetes (T2DM) by 160 weeks defined by fasting glycaemia, OGTT and/or HbA1c according to the ADA criteria1	—

Secondary

Measure	Time frame
Secondary outcomes by 160 weeks (end of treatment) and by 172-184 weeks (3-6 months after stop medication): such as need for rescue therapy for diabetes, prediabe, regression to normoglycaemia, mean BMI, waist circumference, waist/hip circumference, weight loss ≥5%, ≥10% and ≥15%, body fat percentage measured by bioelectrical impedance analysis and Beta-cell function	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026